Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash
Source: SeekingAlpha
2025-07-31 00:01:40 ET
Thesis
Janux Therapeutics ( JANX )’s know-how and scientific development have raised a lot of interest among investors, as well as numerous buy-out rumors. Although I would not discard the possibility of a buyout, I want to center my analysis on the company’s pipeline updates, and current financial status....
Read the full article on Seeking Alpha
For further details see:
Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash
Janux Therapeutics Inc.
NASDAQ: JANX
JANX Trading
2.65% G/L:
$13.965 Last:
401,319 Volume:
$13.67 Open:
JANX Latest News
February 26, 2026 04:01:00 pm
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
February 17, 2026 07:00:00 am
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
January 26, 2026 07:00:00 am
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer
JANX Stock Data
$789,139,228
45,531,890
1.75%
55
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
